Every 424B that Cibus, Inc. (CBUS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CBUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBUS filings page.
Cibus, Inc. is registering 10,738,040 shares of Class A Common Stock issuable upon exercise of outstanding warrants.
This prospectus covers the issuance of those shares upon warrant exercise and states that the Company will receive proceeds from such exercises. The prospectus discloses assumed share counts of 76,345,736 shares outstanding as of March 31, 2026 and presents dilution and tax-related information, including a net tangible book value (deficit) of $(228.3) million, or $(2.99) per share as of March 31, 2026. The Company states it intends to use net proceeds, if any, for working capital and to fund development of its Rice weed management traits.
Cibus, Inc. is offering up to $50,000,000 of Class A Common Stock in an at-the-market program pursuant to a Sales Agreement with Jefferies LLC.
The offering permits Cibus to sell shares from time to time through Jefferies as agent, with Jefferies receiving a 3.0% commission. Net proceeds are intended for working capital and general corporate purposes, including further development of Rice herbicide tolerance traits and facilities-related costs.
Cibus, Inc. is offering 6,976,744 shares of Class A Common Stock at $2.15 per share. The offering includes a 30-day underwriter option to purchase up to an additional 1,046,511 shares and is expected to deliver on or about March 27, 2026. Net proceeds are estimated at approximately $13.5 million (or approximately $16.0 million if the option is exercised in full).
The company intends to use proceeds for working capital and to fund further development of its Rice weed management traits. Financial context disclosed: as of December 31, 2025, Cibus reported $9.9 million in cash and cash equivalents and $16.9 million in current liabilities, and the audit report contains a going concern explanatory paragraph.
Cibus, Inc. is offering shares of its Class A Common Stock and pre-funded warrants pursuant to a preliminary prospectus supplement dated March 25, 2026. The offering is being sold on a firm commitment underwritten basis with a 30-day option for additional shares.
The filing discloses $9.9 million of cash and cash equivalents and $16.9 million of current liabilities as of December 31, 2025, and states there is substantial doubt about Cibus’ ability to continue as a going concern without additional financing. The company intends to use net proceeds for working capital and continued development of its Rice herbicide tolerance traits.
Cibus, Inc. is conducting a primary underwritten offering of 13,333,333 shares of Class A common stock at $1.50 per share, with gross proceeds of about $20.0 million and estimated net proceeds of approximately $17.8 million before any exercise of the underwriter’s option for 1,999,999 additional shares.
The company plans to use the cash mainly for working capital and general corporate purposes, including further development of its weed management traits in Rice and payment of accrued advisory fees, including about $2.4 million owed to Ducera. Members of the board are purchasing 999,999 shares at the public price, and CBUS remains listed on Nasdaq.
Cibus highlights significant dilution: its net tangible book value was $(4.04) per share as of September 30, 2025, and investors in this deal face immediate dilution of about $4.46 per share. The company had $23.9 million in cash and cash equivalents and $20.6 million in current liabilities as of that date, is targeting annual net cash usage of roughly $30 million in 2026, and warns that it still needs additional financing and could ultimately be forced to wind down through bankruptcy, potentially leaving shareholders with little or no recovery.
Cibus, Inc. plans an underwritten public offering of Class A common stock on Nasdaq to raise cash for operations and its rice weed-management trait programs. Board members may buy up to approximately $1.5 million of shares at the public price, and BTIG is the sole bookrunner with a 30‑day option to purchase additional shares.
Cibus highlights significant going concern risks. As of September 30, 2025, it held $23.9 million in cash and cash equivalents against $20.6 million in current liabilities, and it is targeting annual net cash usage of about $30 million or less during 2026 after restructuring and workforce reductions.
The company is focusing capital on herbicide-tolerant rice traits, which management believes could ultimately support annual accessible royalties of over $200 million in initial markets, while pursuing partner-funded programs in biofragrances and lauric oils. A special board committee is exploring strategic alternatives, including financings, business combinations, asset sales and licensing, and warns that failure to secure sufficient capital could lead to a wind-down in which shareholders may lose most or all of their investment.